General - Additional Information (Detail)	1 Months Ended		3 Months Ended		6 Months Ended				6 Months Ended	1 Months Ended	6 Months Ended	12 Months Ended					1 Months Ended	6 Months Ended				12 Months Ended
	Jun. 11, 2013 USD ($)	Mar. 28, 2013	Jun. 30, 2013 USD ($)	Jun. 30, 2012	Jun. 30, 2013 USD ($)	Jun. 30, 2012	Dec. 31, 2012 USD ($)	May 01, 2013 Actavis [Member] USD ($)	Jun. 30, 2013 Royalty on 18mg [Member]	Mar. 28, 2013 Actavis Group [Member]	Jun. 30, 2013 Actavis Group [Member] Ratio	Dec. 31, 2012 Actavis Group [Member]	Oct. 31, 2012 Actavis Group [Member] USD ($)	Oct. 31, 2012 Actavis Group [Member] EUR (€)	Jun. 30, 2013 Uteron Pharma, SA [Member] USD ($)	Jan. 23, 2013 Uteron Pharma, SA [Member] USD ($)	May 17, 2013 Warner Chilcott Plc [Member] Ratio	Jun. 30, 2013 Warner Chilcott Plc [Member] USD ($)	May 19, 2013 Warner Chilcott Plc [Member] USD ($)	Jun. 30, 2013 Medicines360 [Member] USD ($)	Jun. 30, 2013 License agreement [Member] USD ($)	Dec. 31, 2012 Minimum [Member]	Dec. 31, 2012 Maximum [Member]
Business Acquisition [Line Items]
Business acquisition date																		May 19, 2013
Acquisition through stock-for-stock transaction																			$ 8,500,000,000
Share exchange ratio											1						0.16
Acquisition costs																		22,600,000
Cash paid for acquisition													5,469,800,000	4,219,700,000		142,000,000
Assumption of debt																7,700,000
Potential milestone payments																155,000,000
Maximum number of shares issuable for contingent consideration													5,500,000	5,500,000
Cash paid to acquire product								57,000,000
Cash paid to acquire rights to market, sell and distribute medicine	52,300,000
Milestone payments	125,000,000
Acquisition of intangible assets relating to IPR&D													272,900,000		250,000,000	250,000,000				190,400,000
Acquisition of intangible assets relating to prepaid R&D																				6,700,000
Contingent consideration																					144,800,000
Royalty payable to Ortho-Mcneil-Janssen Pharmaceuticals Inc					30.00%				30.00%													50.00%	55.00%
Common stock, shares authorized			500,000,000		500,000,000		500,000,000
Common stock, par value			$ 0.0033		$ 0.0033		$ 0.0033						$ 0.0033
Common stock, shares issued			143,700,000		143,700,000		138,000,000
Common stock, shares outstanding			133,200,000		133,200,000		127,700,000
Treasury stock, shares			10,500,000		10,500,000		10,300,000
Large wholesalers represent the Company's chargeback payments, minimum					85.00%
Large wholesalers represent the Company's chargeback payments, maximum					90.00%
Accounts receivable are presented net of sales returns and allowances balances			1,016,200,000		1,016,200,000		814,300,000
Sales returns and allowances in accounts receivable increase (decrease)					201,900,000
Increase in sales volume of products					78,800,000
Increase in sales returns accruals			10,600,000		10,600,000
Sales return allowance included in the accounts payable and accrued expenses			586,000,000		586,000,000		634,400,000
Sales returns and allowances in accounts payable and accrued expenses increase decrease					48,400,000
Increase in annual rebate accruals			79,000,000		79,000,000
Increase in chargebacks due to increased purchase by wholesalers					33,400,000
Increase in payments of rebates			16,100,000		16,100,000
Increase in Sales Returns and Allowances accounts receivable rebates					12,900,000
Medicaid rebates			20,000,000		20,000,000
IPR&D impairment					4,400,000
Goodwill impairment					647,500,000
Stock awards to purchase		1,650,000	2,000,000	1,800,000	2,200,000	1,900,000
Weighted average number of shares, contingently issuable			3,850,000		3,850,000					1,650,000		3,850,000
Total unrecognized compensation expense, net of estimated forfeitures			83,600,000		83,600,000
Remaining weighted average period (years)					2 years 9 months 18 days
Restricted stock grants and performance-based awards issued					765,000
Aggregate intrinsic value of restricted stock grants and performance-based awards					67,100,000
Stock option grants issued					225,000
Aggregate fair value of stock options grant					$ 4,900,000